News for CGIX Stock

Cancer Genetics and StemoniX Announce Merger Closing Cancer Genetics Announces Shareholder Approval of All Proposals in Connection with the Proposed Merger with StemoniX Cancer Genetics Announces Roland J. Carrillo, PhD as Vice President of Business Development Cancer Genetics to Present at the Annual 33rd ROTH Conference Cancer Genetics to Present at the H.C. Wainwright Global Life Sciences Conference Cancer Genetics Announces Closing of $17.5 Million Common Stock Offering Priced At-the-Market under Nasdaq Rules Cancer Genetics Announces $17.5 Million Common Stock Offering Priced At-the-Market under Nasdaq Rules Cancer Genetics Announces Closing of $10.0 Million Private Placement Priced At-the-Market Cancer Genetics Announces $10.0 Million Private Placement Priced At-the-Market Cancer Genetics to Present at the 2021 BioConnect Virtual Conference Hosted by H.C. Wainwright Cancer Genetics Reports Third Quarter 2020 Financial Results Cancer Genetics, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriter’s Option to Purchase Additional Shares Cancer Genetics, Inc. Increases Previously Announced Bought Deal to $3.0 Million Cancer Genetics, Inc. Announces $2.0 Million Bought Deal Offering Cancer Genetics Announces Participation at the 22nd Annual Rodman & Renshaw Global Investment Conference Cancer Genetics and StemoniX Sign Definitive Agreement to Merge Cancer Genetics Reports Second Quarter 2020 Financial Results Cancer Genetics Reports First Quarter 2020 Financial Results and Provides Strategic Business Updates